Are peptide clinics legal in the UK?
A UK peptide clinic can be entirely lawful, partly lawful, or operating outside the medicines framework — and the difference usually doesn't show up in the branding. This page maps the registrations that should be in place and the questions a prospective patient (or compliance reviewer) should ask.
The three regulatory layers
A lawful UK peptide-prescribing clinic sits at the intersection of three regulators. None of them are optional.
- The prescriber. Must be a healthcare professional with prescribing rights — most commonly a GMC-registered doctor, but also independent-prescriber pharmacists (GPhC) and nurse / physiotherapist prescribers (NMC / HCPC) with the relevant qualification. The GMC register should name the doctor and show their scope of practice.
- The dispensing pharmacy. The pharmacy that actually supplies the medicine must be on the GPhC register (or the PSNI register in Northern Ireland). Online clinics commonly use a partner pharmacy; that partner should be identifiable.
- The premises (England). A clinic carrying out regulated activities in England must be registered with the Care Quality Commission (CQC). Scotland uses Healthcare Improvement Scotland (HIS); Wales, HIW; Northern Ireland, RQIA. Cosmetic procedures and weight-loss services frequently fall within scope.
A real, lawful clinic can name all three. If a clinic refuses to name the prescribing clinician or the dispensing pharmacy (“our prescriber will be in touch”, “dispensed from a UK-registered pharmacy” without naming it), that is a serious red flag.
Licensed peptide medicines a UK clinic can prescribe
- Semaglutide — Wegovy (weight management), Ozempic (T2DM), Rybelsus (oral T2DM). All UK-licensed POMs.
- Tirzepatide — Mounjaro (T2DM and weight management). UK-licensed POM.
- Liraglutide — Saxenda (weight management), Victoza (T2DM). UK-licensed POMs.
- Other licensed peptide medicines — teriparatide (osteoporosis), goserelin / leuprolide (oncology, endocrinology), calcitonin, octreotide. These are not weight-management or performance peptides; they have specialist indications.
Unlicensed peptides and clinics
The harder question is whether a UK clinic can lawfully offer unlicensed peptides — BPC-157, TB-500, CJC-1295, ipamorelin, MOTS-c, AOD-9604, melanotan II, and so on.
UK law permits a prescriber to prescribe an unlicensed medicinal product under specific conditions (the “specials” framework in HMR 2012 Part 12), but the conditions are narrow: there must be a special clinical need that no licensed product can meet, the prescriber must take personal clinical responsibility, and the product must be manufactured by a holder of a manufacturer’s “specials” licence (MS). A clinic that simply orders BPC-157 from a research-chemical supplier and dispenses it is not operating within the specials framework.
See the separate page on compounded peptides in the UK for more on what a lawful “specials” supply looks like and what it isn’t.
Advertising and claims
UK clinic advertising is subject to the CAP code (non-broadcast) and BCAP code (broadcast), enforced by the ASA, alongside HMR 2012 advertising rules for POMs (which prohibit advertising POMs to the general public). For peptides specifically, frequent ASA findings include:
- Implied medicinal claims (“heals”, “regenerates”, “reverses”) for unlicensed substances.
- Before-and-after photography that misrepresents typical results.
- Direct-to-consumer promotion of POMs (a per-se HMR breach for POM advertising aimed at the public).
See peptide advertising rules for the full picture.
Patient checks before engaging a UK peptide clinic
- Look up the prescriber on the GMC register; confirm name, scope, and any conditions on practice.
- Look up the dispensing pharmacy on the GPhC (or PSNI) register. If the clinic won’t name it, walk away.
- For premises-based clinics in England, check the CQC inspection report.
- Confirm a real clinical assessment (history, contraindications, mental-health screen for weight-management prescribing, baseline bloods where indicated). A 60-second online form is not a clinical assessment.
- Ask which manufacturer the medicine comes from. Licensed GLP-1s ship in their branded device with a PIL; “compounded semaglutide” in a generic vial is a different supply entirely.
Red-flag claims
If you see wording like this on a seller, clinic, or social-media advert, treat it as a warning sign rather than a benefit.
“Our peptide clinic offers BPC-157 and TB-500 for sports injuries”
Neither has a UK marketing authorisation. Offering them for a human health indication crosses into unlicensed-medicines territory regardless of clinic branding.
“Compounded semaglutide — same active ingredient at half the price”
Lawful UK ‘specials’ supply is narrow. Mass-market compounded semaglutide marketed on price is the pattern MHRA has acted against in the GLP-1 space.
“Doctor-prescribed — but we don't share our prescriber's details”
A lawful prescriber can be named and looked up on the GMC register. Refusing to name them is incompatible with regulated practice.
“No GP letter needed — fill in our 60-second form”
GLP-1 prescribing requires a genuine clinical assessment including mental-health screening and contraindication check. A 60-second form is not it.
“Anti-ageing peptide therapy — guaranteed results”
‘Guaranteed results’ is a per-se CAP code breach for any health claim, and especially for unlicensed substances.
Sources & further reading
- GMC — The Medical Register — gmc-uk.org
- GPhC — Online registers — pharmacyregulation.org
- CQC — cqc.org.uk
- Human Medicines Regulations 2012 — legislation.gov.uk
- ASA / CAP advertising codes — asa.org.uk
Frequently asked questions
- Can a UK clinic legally prescribe peptides?
- A GMC-registered prescriber can lawfully prescribe a UK-licensed medicine on a private prescription where clinically appropriate — semaglutide (Wegovy / Ozempic), tirzepatide (Mounjaro), and liraglutide (Saxenda) are the main licensed weight-management peptides in the UK. Unlicensed “research peptides” are a different category and require a much harder justification to prescribe lawfully.
- What registrations should a UK peptide clinic have?
- At minimum: the prescriber on the GMC register, the dispensing pharmacy on the GPhC register (PSNI for Northern Ireland), and (in England) the clinic premises on the CQC register if it provides regulated activities. Devolved nations have equivalent inspectorates (HIS in Scotland, HIW in Wales, RQIA in Northern Ireland).
- Is it lawful for a clinic to offer BPC-157 or TB-500?
- These peptides have no UK marketing authorisation. A clinic offering them as treatment for injuries, gut healing, or anti-ageing is presenting an unlicensed product as a medicine, which engages MHRA's remit and creates clinical-governance questions about what the prescriber is taking responsibility for.
- What if the clinic calls it a “consultation” rather than a “prescription”?
- The framing doesn't change the underlying activity. If a clinician is supplying or directing the use of an unlicensed compound for a human health purpose, the regulatory analysis applies.
- Where do I check a UK clinic?
- GMC register for the prescriber, GPhC (or PSNI) register for the pharmacy, CQC (or HIS/HIW/RQIA) register for the premises. If the clinic refuses to name the prescribing clinician or the dispensing pharmacy, that is a red flag.